Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis

Trial Profile

A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms ORAL-Sequel
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Nov 2018 Results assessing Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in RA patients using data from NCT00853385, NCT01039688, NCT00147498, NCT00413660, NCT00550446, CT02147587 and NCT00413699 sub-studies), published in the Arthritis and Rheumatology
    • 24 Oct 2018 Results of pooled data 2 LTE studies (NCT00413699 [ORAL Sequel LTE main study database locked at time of analysis: March 2017] and NCT00661661) assessing patient Characteristics Associated with Discontinuation of Tofacitinib, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top